Insomnia.Fatigue

The SSRIs produce fewer sedative, anticholinergic, and cardiovascular adverse effects than the TCAs and are less likely to cause weight gain than the TCAs. The primary adverse effects include nausea, vomiting, diarrhea, headache, insomnia, fatigue, and sexual dysfunction. A few patients have anxiety symptoms early in treatment. 

Vomiting, arthralgia, rhinitis, insomnia, fatigue, flatulence, coughing, dyspepsia... 

Anorexia, headache, vomiting, flatulence, dizziness, somnolence, insomnia, fatigue, hearing impairment... 

Edema, weight change, breast tenderness, nervousness, insomnia, fatigue, dizziness Rare... 

Abdominal pain, bronchitis, dizziness, headache, cough, insomnia, fatigue, vertigo Serious Reactions... 

Insomnia, fatigue, heartburn, abdominal pain, dizziness, headache, diarrhea, nausea, vomiting, arthralgia, edema... 

Insomnia, fatigue, nausea, motor activation, increased tics, suicidal ideation... 

Approximately 5% of women in the child-bearing years will have prominent mood and physical symptoms during the late luteal phase of almost every cycle these may include anxiety, depressed mood, irritability, insomnia, fatigue, and a variety of other physical symptoms. These symptoms are more severe than those typically seen in premenstrual syndrome (PMS) and can be quite disruptive to vocational and interpersonal activities. The SSRIs are known to be beneficial to many women with PMDD, and fluoxetine and sertraline have been approved for this indication. Treating for 2 weeks out of the month in the luteal phase may be as effective as continuous treatment. The rapid effects of SSRIs in PMDD may be associated with rapid increases in pregnenolone levels. 

Potential adverse effects are headache, dizziness, insomnia, fatigue, and gastrointestinal discomfort, although these are typically mild. Lamivudine s bioavailability increases when it is -administered with trimethoprim-sulfamethoxazole. Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another therefore, their concurrent use should be avoided if possible. Short-term safety of lamivudine has been demonstrated for both mother and infant. 

Pantothenate deficiency is rare, occurring only in cases of severe malnutrition characteristic symptoms include vomiting, intestinal distress, insomnia, fatigue and occasional diarrhoea. Pantothenate is widespread in foods meat, fish, poulty, whole-grain cereals and legumes are particularly good sources. Although no RDA or RNI value has been established for panthothenate, safe and adequate intake of this vitamin for adults is estimated to be 3-7 mg day-1. Pantothenate is non-toxic at doses up to 10 g day-1. 

Adverse Reactions Adverse events with a higher incidence in fiuvastatin-treated patients than placebo patients Arthropathy Exercise-related muscle pain Sinusitis Bronchitis Dyspepsia Diarrhea Abdominal pain Nausea Insomnia Fatigue Abdominal pain Asthenia Constipation Diarrhea Dyspepsia Flatulence Nausea Headache Upper respiratory tract infection Headache Constipation Flatulence Dyspepsia Abdominal pain Arthralgia Myalgia Bronchitis Pruritus Rhabdomyolysis Increases in serum transaminases and CPK... 

Corrected low white cell count (rats, dogs) counteracted H37Rv (mice) anticoagulant, increased liver protein (rat) in humans, raised white cell counts in most cases, also treated cancer, migraine, insomnia, fatigue 173... 

Many depressed pafienfs only have a partial response where some symptoms are improved but others persist (especially insomnia, fatigue, and problems concentrating)... 

---